Final 3‐year clinical outcomes following transcatheter aortic valve implantation with a supra‐annular self‐expanding repositionable valve in a real‐world setting: Results from the multicenter FORWARD study

Figures

• 

  FIGURE 1. Patient dispositionNumber of patients with completed follow‐up as a proportion of the number of patients with expected follow‐up. Patients who died were not lost to follow‐up and counted as known status for each time point [Color figure can be viewed at wileyonlinelibrary.com]

• 

  FIGURE 2. All‐cause mortality through 3 years for patients with and without a new permanent pacemaker implantation and based on the severity of core‐laboratory assessed paravalvular regurgitation measured at discharge.Landmark analysis of all‐cause mortality at 3 years for patients with compared to patients without a new permanent pacemaker implantation (PPI) within 30 days post‐TAVR (A). *Number of patients at risk at day 31. Patients with a baseline PPI and those who died within 30 days post‐procedure were excluded. p‐value based on log‐rank test. Kaplan–Meier estimates of all‐cause mortality for patients with no or trace compared with those with mild or more paravalvular regurgitation (PVR) at discharge (B). Day 0 was the date the echocardiogram was performed. p‐value based on the log‐rank test [Color figure can be viewed at wileyonlinelibrary.com]

• 

  FIGURE 3. Landmark analysis of new serious adverse events.Landmark analysis of all‐cause mortality (A), stroke (B), and new permanent pacemaker (C) at 1 and 2 years [Color figure can be viewed at wileyonlinelibrary.com]

• 

  FIGURE 4. Change in New York Heart Association Class from BaselineChange in New York Heart Association classification from baseline to each annual follow‐up. Change was defined as moving from 1 NYHA classification to another [Color figure can be viewed at wileyonlinelibrary.com]